stockrow
Monday 9 November 2026
Export EVMN’s income statement to Excel — free account
Evommune Inc.
EVMNEvommune Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.0 million, up 85.7% from fiscal 2024.
- EPS
- +89.9%
- Free cash flow
- +21.8%
Quarter to June 2026, against a year earlier
6.65
0.28
+4.40%
Follow EVMN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (141.99%) | 0.00% | 0.00% | 0.00% |
+4 more TTM periods Free account |
|
| (62.71%) | (47.13%) | (61.23%) | (133.69%) | ||
ROIC |
(82.46%) | (60.08%) | (89.61%) | 0.00% | |
Return on Tangible Assets |
(50.25%) | (36.73%) | (50.43%) | (77.95%) | |
Free Cash Flow per Share |
(2.07) | (2.39) | (12.51) | (50.65) | |
Free Cash Flow |
(74.65) | (80.36) | (76.76) | (78.25) | |
Capital Expenditures |
(0.50) | (0.32) | (0.32) | — | |
| Other line items | |||||
Cash ROIC |
(15.59%) | (15.56%) | (21.63%) | 73.08% | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 1.05 | 1.11 | 1.38 | |
Depreciation/Fixed assets |
0.40 | 0.61 | 1.40 | 1.47 | |
Capex/Depreciation |
(0.76) | (0.32) | (0.23) | 0.00 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(2.05) | (2.38) | (12.46) | (50.65) | |
Capex per Share |
(0.01) | (0.01) | (0.05) | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 25 Oct 2026